Marc Sandberg, MD
Endocrinology, Diabetes & Metabolism · Flemington, NJNPI 1770557837
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $509,138 of the $566,757 with a category attached, or 89.8%. 60 manufacturers reported payments, led by Lilly USA, LLC at 33.0% of the total. Reporting peaked in 2019 at $123,159 and has fallen 62.2% since, to $46,524 in 2025. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,603 payments — averaging $353.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$187K
- Sanofi-aventis U.S. LLC$149K
- Novo Nordisk$111K
- Boehringer Ingelheim$27K
- Valeritas, Inc.$25K
- Corcept Therapeutics$16K
- plus $53K from 54 others
What the payments were for
- Consulting fees$13,0842%
- Speaking & faculty fees$509,13890%
- Travel & lodging$20,6754%
- Food & beverage$23,4694%
- Education$3910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$81,266
- SOLIQUA 100/33$64,181
- JARDIANCE$60,934
- Ozempic$56,807
- TOUJEO$47,707
- HUMULIN$42,400
- RYBELSUS$35,126
- TZIELD$26,685
- V-GO$26,077
- LYUMJEV$14,300
- Korlym$14,213
- Pogo Automatic Blood Glucose Monitoring System$10,025
- FARXIGA$9,853
- Synthroid$7,700
- Tresiba$6,685
- INVOKANA$5,923
- Xultophy 100/3.6$5,889
- UNITHROID$2,750
- ZEGALOGUE$2,000
- ISTURISA$2,000
How this compares
$566,757 in reported general payments places this provider in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 486 | $661,407 |
| TrulicityDulaglutide | 321 | $455,014 |
| MounjaroTirzepatide | 318 | $403,419 |
| JardianceEmpagliflozin | 293 | $295,280 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 163 | $225,868 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 196 | $213,359 |
| Tresiba Flextouch U-200Insulin Degludec | 171 | $160,134 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 109 | $110,050 |
| FarxigaDapagliflozin Propanediol | 55 | $83,586 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 55 | $74,476 |
| Xigduo XrDapaglifloz Propaned/Metformin | 55 | $67,614 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 87 | $66,301 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 39 | $64,174 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 32 | $60,742 |
| TradjentaLinagliptin | 69 | $55,683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev, Humalog | $186,922 | $920,959727 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $110,905 | $766,738580 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $26,995 | $593,413590 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $148,820 | $225,868163 claims |
| AstraZenecaFarxiga | $10,417 | $83,58655 claims |
| MerckJanuvia, Janumet Xr | $132 | $73,34069 claims |
| AbbVieSynthroid | $8,079 | $41,514367 claims |
| AmgenProlia | $637 | $20,63512 claims |
| Amneal Pharmaceuticals LLCUnithroid | $3,329 | $9,327300 claims |
| IBSA Pharma Inc.Tirosint | $110 | $7,67321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Flemington
- Robert LindFlemington$32K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.